Roche Partners with Nurix to Advance BTK Degrader Bexobrutideg Across Cancer, Immunology and Neurology
BASEL, Switzerland, June 8, 2026 Roche announced a global licensing and collaboration agreement with Nurix Therapeutics to co-develop and...
CLL
Advertisement
AbbVie Secures EU Approval for Expanded VENCLYXTO Use in First-Line CLL
NORTH CHICAGO, Ill., May 29, 2026 AbbVie announced that the European Commission (EC) has approved an expanded label for...
BeOne Sets New CLL Benchmark with 78-Month BRUKINSA Data at ASCO 2026
SAN CARLOS, Calif. | May 29, 2026 BeOne Medicines presented groundbreaking long-term data at the 2026 American Society of...
Nurix Therapeutics Showcases Bexobrutideg Data at EHA
BRISBANE, Calif., May 12, 2026 Nurix Therapeutics announced that updated clinical data for its investigational BTK degrader bexobrutideg (NX-5948)...
Ascentage Pharma Highlights Hematology Pipeline at EHA
ROCKVILLE, Md. and SUZHOU, China, May 12, 2026 Ascentage Pharma announced that 17 major clinical advances across its hematology...
Advertisements
Eli Lilly Reports Breakthrough Phase 3 Jaypirca Results
Indianapolis, Indiana | April 13, 2026 Eli Lilly and Company has announced positive topline results from the Phase 3...
Jaypirca Gains Approval as First Non-Covalent BTK Inhibitor for CLL/SLL
INDIANAPOLIS, September 8, 2025 — Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, has demonstrated a...
Advertisement
